<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35963844</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>16</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Aug</Month><Day>13</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Vaccine effectiveness of CoronaVac against COVID-19 among children in Brazil during the Omicron period.</ArticleTitle><Pagination><StartPage>4756</StartPage><MedlinePgn>4756</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">4756</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-022-32524-5</ELocationID><Abstract><AbstractText>Although severe COVID-19 in children is rare, they may develop multisystem inflammatory syndrome, long-COVID and downstream effects of COVID-19, including social isolation and disruption of education. Data on the effectiveness of the CoronaVac vaccine is scarce during the Omicron period. In Brazil, children between 6 to 11 years are eligible to receive the CoronaVac vaccine. We conducted a test-negative design to estimate vaccine effectiveness using 197,958 tests from January 21, 2022, to April 15, 2022, during the Omicron dominant period in Brazil among children aged 6 to 11 years. The estimated vaccine effectiveness for symptomatic infection was 39.8% (95% CI 33.7-45.4) at &#x2265;14 days post-second dose. For hospital admission vaccine effectiveness was 59.2% (95% CI 11.3-84.5) at &#x2265;14 days. Two doses of CoronaVac in children during the Omicron period showed low levels of protection against symptomatic infection, and modest levels against severe illness.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Florentino</LastName><ForeName>Pilar T V</ForeName><Initials>PTV</Initials><Identifier Source="ORCID">0000-0001-8077-8100</Identifier><AffiliationInfo><Affiliation>Centre of Data and Knowledge Integration for Health (CIDACS), Instituto Gon&#xe7;alo Moniz Institute, Oswaldo Cruz Foundation (Fiocruz), Salvador, Brazil. pilar.veras@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Science Institute, University of S&#xe3;o Paulo, S&#xe3;o Paulo, Brazil. pilar.veras@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alves</LastName><ForeName>Fl&#xe1;via J O</ForeName><Initials>FJO</Initials><Identifier Source="ORCID">0000-0003-1613-2270</Identifier><AffiliationInfo><Affiliation>Centre of Data and Knowledge Integration for Health (CIDACS), Instituto Gon&#xe7;alo Moniz Institute, Oswaldo Cruz Foundation (Fiocruz), Salvador, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cerqueira-Silva</LastName><ForeName>Thiago</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-4534-2509</Identifier><AffiliationInfo><Affiliation>Gon&#xe7;alo Moniz Institute, Oswaldo Cruz Foundation (Fiocruz), Salvador, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, Federal University of Bahia, Salvador, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oliveira</LastName><ForeName>Vinicius de Ara&#xfa;jo</ForeName><Initials>VA</Initials><Identifier Source="ORCID">0000-0001-7858-9650</Identifier><AffiliationInfo><Affiliation>Centre of Data and Knowledge Integration for Health (CIDACS), Instituto Gon&#xe7;alo Moniz Institute, Oswaldo Cruz Foundation (Fiocruz), Salvador, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, Federal University of Bahia, Salvador, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>J&#xfa;nior</LastName><ForeName>Juracy B S</ForeName><Initials>JBS</Initials><AffiliationInfo><Affiliation>Public Health Institute, Federal University of Bahia, Salvador, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jantsch</LastName><ForeName>Adelson G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Gon&#xe7;alo Moniz Institute, Oswaldo Cruz Foundation (Fiocruz), Salvador, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Penna</LastName><ForeName>Gerson O</ForeName><Initials>GO</Initials><Identifier Source="ORCID">0000-0001-8967-536X</Identifier><AffiliationInfo><Affiliation>Tropical Medicine Centre, University of Bras&#xed;lia, Fiocruz School of Government, Bras&#xed;lia, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boaventura</LastName><ForeName>Viviane</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Gon&#xe7;alo Moniz Institute, Oswaldo Cruz Foundation (Fiocruz), Salvador, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, Federal University of Bahia, Salvador, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Werneck</LastName><ForeName>Guilherme L</ForeName><Initials>GL</Initials><Identifier Source="ORCID">0000-0003-1169-1436</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology, Social Medicine Institute, State University of Rio de Janeiro, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Collective Health Studies, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodrigues</LastName><ForeName>Laura C</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>London School of Hygiene and Tropical Medicine, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pearce</LastName><ForeName>Neil</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>London School of Hygiene and Tropical Medicine, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barral-Netto</LastName><ForeName>Manoel</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-5823-7903</Identifier><AffiliationInfo><Affiliation>Centre of Data and Knowledge Integration for Health (CIDACS), Instituto Gon&#xe7;alo Moniz Institute, Oswaldo Cruz Foundation (Fiocruz), Salvador, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, Federal University of Bahia, Salvador, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barreto</LastName><ForeName>Mauricio L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Centre of Data and Knowledge Integration for Health (CIDACS), Instituto Gon&#xe7;alo Moniz Institute, Oswaldo Cruz Foundation (Fiocruz), Salvador, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paix&#xe3;o</LastName><ForeName>Enny S</ForeName><Initials>ES</Initials><Identifier Source="ORCID">0000-0002-4797-908X</Identifier><AffiliationInfo><Affiliation>London School of Hygiene and Tropical Medicine, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>213589/Z/18/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Disease" UI="C000705967">pediatric multisystem inflammatory disease, COVID-19 related</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001938" MajorTopicYN="N" Type="Geographic">Brazil</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018746" MajorTopicYN="N">Systemic Inflammatory Response Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000087507" MajorTopicYN="N">Vaccine Efficacy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>M.B.-N. reports grants from the Fazer o bem faz bem program from JBS. S.A. V.dA.O., V.B., M.L.B., and M.B.-N. are employees of Fiocruz, a federal public institution, which manufactures Vaxzevria in Brazil, through a full technology transfer agreement with AstraZeneca. Fiocruz allocates all its manufactured products to the Ministry of Health for public health use. The remaining authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>13</Day><Hour>23</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>8</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35963844</ArticleId><ArticleId IdType="pmc">PMC9375192</ArticleId><ArticleId IdType="doi">10.1038/s41467-022-32524-5</ArticleId><ArticleId IdType="pii">10.1038/s41467-022-32524-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Frenck RW, et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. N. Engl. J. Med. 2021;385:239&#x2013;250. doi: 10.1056/NEJMoa2107456.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2107456</ArticleId><ArticleId IdType="pmc">PMC8174030</ArticleId><ArticleId IdType="pubmed">34043894</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter EB, et al. Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age. N. Engl. J. Med. 2022;386:35&#x2013;46. doi: 10.1056/NEJMoa2116298.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2116298</ArticleId><ArticleId IdType="pmc">PMC8609605</ArticleId><ArticleId IdType="pubmed">34752019</ArticleId></ArticleIdList></Reference><Reference><Citation>Center for Disease Control and Prevention. Multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019 (COVID-19). (2020). Available at: https://emergency.cdc.gov/han/2020/han00432.asp. (Accessed: 14th May 2020).</Citation></Reference><Reference><Citation>Stein, M. et al. Project Report The Burden of COVID-19 in children and its prevention by vaccination: a joint statement of the israeli pediatric association and the israeli society for pediatric infectious diseases. Vaccines10, 81 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8781684</ArticleId><ArticleId IdType="pubmed">35062742</ArticleId></ArticleIdList></Reference><Reference><Citation>Minist&#xe9;rio da Sa&#xfa;de do Brasil. Nota T&#xe9;cnica No6/2022-Secovid/Gab/Secovid/Ms. (2022).</Citation></Reference><Reference><Citation>Jara, A. et al. Effectiveness of an inactivated SARS-CoV-2 vaccine in children and adolescents: a large- scale observational study. SSRN (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10117174</ArticleId><ArticleId IdType="pubmed">37155483</ArticleId></ArticleIdList></Reference><Reference><Citation>Jara, A. et al. Effectiveness of CoronaVac in children 3 to 5 years during the omicron SARS-CoV-2 outbreak. Nat. Med.28, 1377&#x2013;1380 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9307483</ArticleId><ArticleId IdType="pubmed">35605637</ArticleId></ArticleIdList></Reference><Reference><Citation>Florentino, P. T. V. et al. Vaccine effectiveness of two-dose BNT162b2 over time against COVID-19 symptomatic infection and severe cases among adolescents: test negative design case control studies in Brazil and Scotland. The Lancet Infectious Diseases. 1&#x2013;23 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9359673</ArticleId><ArticleId IdType="pubmed">35952702</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews N, et al. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N. Engl. J. Med. 2022;386:1532&#x2013;1546. doi: 10.1056/NEJMoa2119451.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2119451</ArticleId><ArticleId IdType="pmc">PMC8908811</ArticleId><ArticleId IdType="pubmed">35249272</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchan, S. A., Nguyen, L., Wilson, S. E., Kitchen, S. A. &amp; Kwong, J. Vaccine effectiveness of BNT162b2 against Omicron and Delta outcomes in adolescents. medRxiv 2022.04.07.22273319 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35706105</ArticleId></ArticleIdList></Reference><Reference><Citation>Veneti L, et al. Vaccine effectiveness with BNT162b2 (Comirnaty, Pfizer-BioNTtech) vaccine against reported SARS-CoV-2 delta and omicron infection among adolescents, Norway, August 2021 to January 2022. SSRN Electron. J. 2022;2:1&#x2013;11.</Citation></Reference><Reference><Citation>Dorabawila, V. et al. Effectiveness of the BNT162b2 vaccine among children 5&#x2013;11 and 12&#x2013;17 years in New York after the emergence of the Omicron Variant. medRxiv 2022.02.25.22271454 (2022).</Citation></Reference><Reference><Citation>Sacco C, et al. Articles Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5&#x2013;11 years in Italy: a retrospective analysis of January-April, 2022. Lancet. 2022;2:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9246475</ArticleId><ArticleId IdType="pubmed">35780801</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandenbroucke J, Pearce N. Test-negative designs differences and commonalities with other case&#x2013;control studies with &#x201c;other patient&#x201d; controls. Epidemiology. 2019;30:838&#x2013;844. doi: 10.1097/EDE.0000000000001088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EDE.0000000000001088</ArticleId><ArticleId IdType="pubmed">31430265</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawood FS, Porucznik CA, Veguilla V, Al E. Incidence rates, household infection risk, and clinical characteristics of SARS-CoV-2 infection among children and adults in Utah and New York City, New York. Jama Pediatrics. 2022;176:59&#x2013;67. doi: 10.1001/jamapediatrics.2021.4217.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapediatrics.2021.4217</ArticleId><ArticleId IdType="pmc">PMC8501415</ArticleId><ArticleId IdType="pubmed">34623377</ArticleId></ArticleIdList></Reference><Reference><Citation>Mensah AA, et al. Risk of SARS-CoV-2 reinfections in children: a prospective national surveillance study between January, 2020, and July, 2021, in England. Lancet Child Adolesc. Health. 2022;6:384&#x2013;392. doi: 10.1016/S2352-4642(22)00059-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-4642(22)00059-1</ArticleId><ArticleId IdType="pmc">PMC8959472</ArticleId><ArticleId IdType="pubmed">35358491</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipsitch M, Goldstein E, Ray GT, Fireman B. Depletion-of-susceptibles bias in influenza vaccine waning studies: how to ensure robust results. Epidemiol. Infect. 2019;147:e306. doi: 10.1017/S0950268819001961.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0950268819001961</ArticleId><ArticleId IdType="pmc">PMC7003633</ArticleId><ArticleId IdType="pubmed">31774051</ArticleId></ArticleIdList></Reference><Reference><Citation>Katikireddi SV, et al. Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil. Lancet. 2022;399:25&#x2013;35. doi: 10.1016/S0140-6736(21)02754-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)02754-9</ArticleId><ArticleId IdType="pmc">PMC8687670</ArticleId><ArticleId IdType="pubmed">34942103</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerqueira-Silva, T. et al. Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil. Nat. Med. 28, 838&#x2013;843 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9018414</ArticleId><ArticleId IdType="pubmed">35140406</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerqueira-Silva, T. et al. Vaccination plus previous infection: protection during the omicron wave in Brazil. Lancet Infect. Dis. 22, 1&#x2013;2 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9110013</ArticleId><ArticleId IdType="pubmed">35588753</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerqueira-Silva T, et al. Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study. Lancet Infect. Dis. 2022;22:791&#x2013;801. doi: 10.1016/S1473-3099(22)00140-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00140-2</ArticleId><ArticleId IdType="pmc">PMC8971277</ArticleId><ArticleId IdType="pubmed">35366959</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandenbroucke JP, Brickley EB, Vandenbroucke-Grauls CMJE, Pearce N. A test-negative design with additional population controls can be used to rapidly study causes of the SARS-COV-2 epidemic. Epidemiology. 2020;31:836&#x2013;843. doi: 10.1097/EDE.0000000000001251.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EDE.0000000000001251</ArticleId><ArticleId IdType="pmc">PMC7523580</ArticleId><ArticleId IdType="pubmed">32841988</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiocruz. GISAID. Rede Gen&#xf4;mica (2020). Available at: http://www.genomahcov.fiocruz.br/#. (Accessed: 15th May 2022)</Citation></Reference><Reference><Citation>Allik, M. et al. Small-area Deprivation Measure for Brazil: Data Documentation. University of Glasgow (2020). Available at: https://researchdata.gla.ac.uk/980/. (Accessed: 15th May 2020).</Citation></Reference><Reference><Citation>Vienna, A. R. Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; (2021).</Citation></Reference><Reference><Citation>Wickham H, et al. Welcome to the Tidyverse Tidyverse package. J. Open Source Softw. 2019;4:1&#x2013;6. doi: 10.21105/joss.01686.</Citation><ArticleIdList><ArticleId IdType="doi">10.21105/joss.01686</ArticleId></ArticleIdList></Reference><Reference><Citation>van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate imputation by chained equations in R. J. Stat. Softw. 2011;45:1&#x2013;67. doi: 10.18637/jss.v045.i03.</Citation><ArticleIdList><ArticleId IdType="doi">10.18637/jss.v045.i03</ArticleId></ArticleIdList></Reference><Reference><Citation>Firth D. &#x201c;Bias reduction of maximum likelihood estimates.&#x201d;. Biometrika. 1995;82:667.</Citation></Reference><Reference><Citation>Benchimol EI, et al. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. PLoS Med. 2015;12:1&#x2013;22. doi: 10.1371/journal.pmed.1001885.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1001885</ArticleId><ArticleId IdType="pmc">PMC4595218</ArticleId><ArticleId IdType="pubmed">26440803</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>